What we do Haleos Labs Limited manufactures and exports pharmaceutical active ingredients and intermediates, operating globally with USFDA and WHO GMP approved facilities in India. |
Founded in 2,006 |
Market share Recognized as a dominant Indian pharma bulk drug exporter with strong global presence in complex APIs and a diversified product portfolio. |
Problem solved Addresses global demand for high-quality, cost-effective pharmaceutical ingredients to support generic and innovator drug manufacturers. |
Top clients or who we serve Serves generic and innovator pharmaceutical companies worldwide; operates primarily B2B with customers in US, Europe, and Asia. |
Key management Managing Director Mr. TVVSN Murthy and Executive Director Mr. TV Praveen have 40+ and 15+ years experience respectively in pharmaceutical sector. |
Our journey and innovations Founded in 2006, evolved from single product to multi-location API manufacturer, successfully passing multiple USFDA audits, expanding capacity and R&D. |
Where we operate Global exports primarily to USA, China, Indonesia, Malaysia, Singapore, Spain, and Brazil, with manufacturing in Hyderabad and Vizag, India. |
Top products or what we offer Active pharmaceutical ingredients (APIs) and intermediates across multiple therapeutic segments with ongoing expansion to 50+ products by FY2028. |
Top brands Flagship products include multiple APIs compliant with USFDA and Japan PMDA standards, contributing to export awards and industry recognition. |
Raw materials needed Specialized chemical compounds and intermediates necessary for API synthesis in pharmaceutical manufacturing. |
Raw materials supplier Multiple global chemical suppliers adhering to stringent quality and regulatory standards supplying raw materials. |
Recurring vs cyclical contribution Revenue is largely recurring via long-term contracts with global pharmaceutical companies with moderate cyclicality based on regulatory approvals. |
Our industry position Well-positioned among Indian API exporters with USFDA approved sites, recognized for quality and regulatory compliance leadership. |
Financial highlights FY25 revenue Rs.344.73 crore with a Net Profit of Rs.20.11 crore, demonstrating robust growth with 11.12% revenue increase year-on-year. |
Geographical revenue split Exports account for approximately 40% of revenue with major markets including the USA and Asia; domestic sales constitute about 55%. |
Order book - |
Whats driving growth Capacity expansion, USFDA approvals, R&D innovation, and global demand for complex, quality APIs are key growth drivers. |
Our future plans Focus on capacity augmentation, expanding product portfolio to 50+ APIs by FY2028, and strengthening global market presence. |
Our green promise Committed to sustainable practices including energy and water conservation, tree planting, and moving towards carbon neutrality. |
Our people and values Over 590 employees fostering a culture of professionalism, integrity, with emphasis on diversity and employee engagement. |
Key challenges ahead Maintaining regulatory compliance globally, managing supply chain risks, and scaling manufacturing efficiently amid market competition. |
Interesting facts Recipient of India Pharma Bulk Drug Company of the Year award 2018 and Outstanding Export Performance award 2019. |
Risks and strategy Risks include regulatory changes and trade policies; mitigated by continuous compliance upgrades and backward integration. |
